Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00833443 · ClinicalTrials.gov registry record · Phase 2
Study of Medical Treatment for Methamphetamine Addiction
A Phase 2 study of Substance Abuse and Methamphetamine-dependence, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
- 1
- Study location
NCT00833443 is a Phase 2 study of Substance Abuse and Methamphetamine-dependence that has completed, run by University of California, Los Angeles. The registered enrollment target is 84 participants, below the 5,258-participant average among 58 other Substance Abuse trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00833443, a Phase 2 study of Substance Abuse and Methamphetamine-dependence, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
- 1
- Study location
Study Summary
Currently there are no medications approved for the treatment of methamphetamine addiction. Bupropion is an antidepressant that is approved by the Food and Drug Administration (FDA) for the treatment of depression and for cigarette smoking cessation but is not approved by the FDA for the treatment of methamphetamine addiction. Preliminary research studies suggest that bupropion may help people receiving treatment for methamphetamine addiction to reduce or to stop their methamphetamine use. But results of these studies also suggest that bupropion may help certain groups of patients more than others, such as men versus women and light versus heavy methamphetamine users, although the reasons for this difference are not known. One possibility is that a person's genetic make up may influence whether or not they respond to treatment with bupropion for methamphetamine addiction. The purpose of the study is to determine if bupropion is can help people reduce or stop their methamphetamine use and to investigate whether genetic variations influence whether people respond to treatment with bupropion for methamphetamine addiction, which may help doctors and patients better decide if treatment with bupropion will be beneficial or not. To identify possible genetic variations that influence response to bupropion, we will perform genetic tests on blood or saliva specimens from participants receiving treatment with either bupropion or placebo (which is a pill that contains no medication) in conjunction with standard cognitive behavioral therapy drug counseling. We will compare methamphetamine use, as assessed with urine drug screens, among participants receiving bupropion versus those receiving placebo to determine if bupropion helps people to reduce or stop their methamphetamine use. We will then compare the results of the genetic tests among participants who respond and who do not respond to bupropion. In addition, since the amount of methamphetamine a person uses was associated
Conditions Studied
Interventions
- DRUG Bupropion
Study Locations (1)
California
- UCLA Clinical Research Site 910 Vine St - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2009-01 |
| Est. Completion | 2013-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00833443
The ClinicalTrials.gov registry entry for NCT00833443 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,258-participant average among 58 other Substance Abuse trials with a reported enrollment target (98% lower). The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Substance Abuse appearing as the primary indexed condition, and to 1 intervention - of which Bupropion is the first listed.
NCT00833443 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00833443 about?
NCT00833443 is a clinical study titled "Study of Medical Treatment for Methamphetamine Addiction". Currently there are no medications approved for the treatment of methamphetamine addiction. Bupropion is an antidepressant that is approved by the Food and Drug Administration (FDA) for the treatment of depression and for cigarette smoking cessation but is not approved by the FDA for the treatment o...
What is the current status of trial NCT00833443?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2009-01. Estimated completion is 2013-07.
What conditions does trial NCT00833443 study?
This clinical trial studies the following conditions: Substance Abuse, Methamphetamine-dependence, Amphetamine Dependence, Methamphetamine, Pharmacogenetics.
What interventions are being tested in trial NCT00833443?
The interventions under investigation include: Bupropion (DRUG).
Who is sponsoring clinical trial NCT00833443?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00833443 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Substance Abuse
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Enhancing Prevention Capacity With Developmental Assets and Getting to Outcomes
COMPLETED · Phase 2
-
Evaluation of Treatments for Homeless Youths
COMPLETED · Phase 2
-
Substance Treatment and HIV Testing and Referral System
COMPLETED · Phase 2
-
Evaluation of Atomoxetine for Cocaine Dependence: A Pilot Trial
COMPLETED · Phase 2
-
Aripiprazole Treatment for Methamphetamine Dependence Among High-risk Individuals
COMPLETED · Phase 2
-
Building Outcomes With Observation-Based Supervision: An FFT Effectiveness Trial
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.